The biotech industry is a marvel among traders and investors because it can double your investment, or halve it, based on a single clinical study. Millions, sometimes billions, of research dollars are poured into developing new drugs and bringing these therapies to market -- $49 billion throughout the entire industry last year, according to PhRMA. However, a vast majority of drugs discovered in the laboratory setting will never see the light of day.
Source: Idaho National Laboratory, Flickr.
Based on data from Medscape, only about one in every 5,000 to 10,000 researched drugs in preclinical trials will be approved by the Food and Drug Administration. This means there's quite the premium given to biotech stocks because of solid clinical data, and quite the haircut when it doesn't pan out.
5 Best China Stocks To Own For 2015: Zygo Corporation(ZIGO)
Zygo Corporation designs, develops, and manufactures ultra-high precision measurement solutions to enhance its customers? manufacturing yields, and optical sub-systems and components for original equipment manufacturer and end-user applications in the Americas, the Far East, and Europe. It operates in two segments, Metrology Solutions and Optical Systems. The Metrology Solutions segment offers 3-Dimensional surface metrology products, precision positioning systems, and custom engineered solutions that are used to measure surface characteristics and critical parameters, including topography and roughness, shape, dimension, thickness, optical characteristics, and defects. This segment primarily provides NewView Series 3D Optical Profilers for fuel injector components; ZeGage to measure and visualize various materials, including rubber, paper, metal, plastic, and ceramics; VeriFire Asphere system that provides high resolution 3-Dimensional surface metrology for aspheric shap ed surfaces; VeriFire Systems, which are optical systems; GPI and VeriFire systems for the defense/aerospace market; and semiconductor products. It serves automotive, consumer electronics, medical, aerospace, military, materials research, optics, flat panel displays, and semiconductor industries. The Optical Systems segment manufactures high precision optical components and electro-optical systems used in the semiconductor, defense, life-sciences, and research markets. It offers defense-related products comprising lenses, windows, freeform optics and assemblies, and meter class optical components; life-science products, such as laser eye correction, dental 3D imaging, and genomic analysis instruments; and custom components and assemblies used in the manufacture of semiconductor chips. The company markets its products through direct sales force, as well as through independent agents and distributors. Zygo Corporation was founded in 1970 and is headquartered in Middlefield, Co nnecticut.
Advisors' Opinion:- [By Monica Gerson]
Zygo (NASDAQ: ZIGO) shares gained 31.06% to touch a new 52-week high of $19.24 after Ametek (NYSE: AME) announced its plans to buy Zygo for about $364 million.
Best Tech Stocks To Own For 2014: Provectus Pharmaceuticals Inc (PVCT)
Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.
PV-10
As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.
PH-10
The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.
Over-the-Counter Pharmaceuticals
The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.
The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.
Advisors' Opinion:- [By Jake L'Ecuyer]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
- [By Luke Jacobi]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
Best Tech Stocks To Own For 2014: Tellabs Inc.(TLAB)
Tellabs, Inc. designs, develops, and supports telecommunications networking products for communication service providers in the United States and internationally. Its products and services enable customers to deliver wireless and wireline voice, data, and video services to business and residential customers. The company operates through three segments: Broadband, Transport, and Services. The Broadband segment provides access products that enable service providers to deliver bundled voice, video, and high-speed Internet/data services over copper or fiber networks; managed access products, which deliver wireless and business services primarily outside of North America; and data products, including packet-switched products that enable wireless and wireline carriers to deliver mobile voice and Internet services, and wireline business services to their customers. The Transport segment enables service providers to manage network bandwidth by adding capacity needed; and wireline and wireless providers to support metro networks, mobile services, and business services for enterprises, as well as triple-play voice, video, and data services for residential consumers. The Services segment delivers deployment, training, support, and professional services, which support various phases of the network, such as planning, building, and operating. Tellabs, Inc. serves primarily communication services providers, including local exchange carriers; wireline and wireless service providers; multiple system operators; competitive service providers; distributors; original equipment manufacturers; system integrators; and government agencies. The company sells its products and services through its direct sales and sales support personnel, value-added resellers, independent sales representatives, distributors, and public and private network providers. Tellabs, Inc. was founded in 1974 and is headquartered in Naperville, Illinois.
Advisors' Opinion:- [By SA Pro Top Ideas]
Stock Movers and Great Calls
Saidal Mohmand argued Wednesday that Tellabs (TLAB) was a strong assets play on the verge of a turnaround. The stock is +5.9% since. Read article » On June 13, Stephen Lin said that Ellie Mae's (ELLI) dominant position could mean 45% upside. Shares are +30.7% since. Read article »
Alpha-Rich long and short ideas regularly move stocks and identify stocks that are about to move. Some notable recent calls subscribers had early access to:To Come Today
Don't forget to check your SA Pro dashboard later today for the latest Alpha-Rich ideas, including a REIT with strong management and many catalysts. Any thoughts to share on the latest Alpha-Rich ideas? Leave a comment here. Have a great weekend.
SA Pro Editors
…............
The SA Pro team is Eli Hoffmann (Editor in Chief), Rachael Granby (Editorial Product Manager), Daniel Shvartsman, Samir Patel, Michael McDonald, and Jeffrey Fischer (Senior Pro Editors). You can reach us at pro-editors@seekingalpha.com.
Best Tech Stocks To Own For 2014: Coherent Inc.(COHR)
Coherent, Inc. provides photonics-based solutions for a range of commercial and scientific research applications worldwide. The company engages in designing, manufacturing, servicing, and marketing lasers, laser tools, precision optics, and related accessories. Its products are used in a range of applications, including microelectronics, scientific research and government programs, original equipment manufacturer components and instrumentation, and materials processing markets. The company markets its products primarily through a direct sales force, as well as through independent representatives. Coherent, Inc. was founded in 1966 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Brian Stoffel]
Rofin-Sinar (NASDAQ: RSTI ) , Coherent (NASDAQ: COHR ) , Newport (NASDAQ: NEWP ) , and JDS Uniphase (NASDAQ: JDSU ) all offer fiber-optic lasers as well.
- [By Evan Niu, CFA]
What: Shares of Coherent (NASDAQ: COHR ) ran higher by as much as 16% after the company reported fiscal second-quarter earnings.
So what: Revenue in the quarter added up to $200.1 million, with adjusted earnings per share of $0.84. Both headline figures were ahead of consensus forecasts, which were perched at $198.2 million in sales and an adjusted profit of $0.80 per share. CEO John Ambroseo said demand in Coherent's commercial end markets improved, resulting in record bookings for materials processing.
- [By Brian Stoffel]
For decades, the standard technology in the laser industry has been the carbon-based laser. In reality, these lasers are still commonly used, and sold in bulk by the likes of Rofin-Sinar (NASDAQ: RSTI ) and Coherent (NASDAQ: COHR ) . They are used largely for precision cutting of large pieces of metal.
Best Tech Stocks To Own For 2014: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By Bryan Murphy]
Anybody who knows at least something about Prosensa Holding NV (NASDAQ:RNA) will at least know the stock turned into a disaster a few weeks ago, plunging from a close of $24.00 on September 19th to a close of $7.14 on September 20th, thanks to the failure of its MS drug drisapersen, which was jointly developed with GlaxoSmithKline plc (NYSE:GSK). Such is the life of a company with only one drug anywhere close to being approved; drisapersen was in Phase 3 trials - RNA shares could have just as easily gained 70% rather than lost 70% had the drug worked.
- [By John Udovich]
It should also be mentioned that earlier in the week, GlaxoSmithKline plc (NYSE: GSK) returned full rights of Duchenne muscular dystrophy drug drisapersen to their partner�Prosensa Holding NV (NASDAQ: RNA) and that news sent shares down 12.48% on�Monday. Moreover,�Prosensa Holding also sank some 70% last fall when Drisapersen failed a phase 3 trial by missing a primary endpoint measuring for how far patients could walk over the course of six minutes (the improvement�wasn't significantly better than the placebo).�However, Prosensa Holding also rose 24.37% yesterday after announcing�initial findings from further analyses from the aggregate data for drisapersen, with the CEO saying:
- [By Garrett Cook]
Prosensa Holding N.V. (NASDAQ: RNA) shares were also up, gaining 8.20 percent to $13.00 on the FDA requirement of additional data from Sarepta on Eteplirsen. Prosensa Holding is also looking to provide a drug to treat Duchenne muscular dystrophy.
- [By Sean Williams]
Shares of Sarepta climbed to a 52-week high of $55.61 in September shortly after an experimental rival drug, drisapersen, developed by Prosensa (NASDAQ: RNA ) and GlaxoSmithKline (NYSE: GSK ) , missed its primary end point by a mile in late-stage trials. However, Sarepta also tanked just weeks later after the Food and Drug Administration decided against supporting an accelerated drug approval for eteplirsen; the agency would not make the connection that increased dystrophin production led to its remarkable trial results.�Also, given the recent failure of drisapersen in a phase 3 study, the FDA felt it pertinent that Sarepta engage in a broader study. Shares ultimately dipped as low as $12.12.�
Best Tech Stocks To Own For 2014: STMicroelectronics N.V.(STM)
STMicroelectronics N.V., an independent semiconductor company, engages in the design, development, manufacture, and marketing of a range of semiconductor integrated circuits and discrete devices. Its products include discrete and standard commodity components, application-specific integrated circuits, custom devices and semi-custom devices, and application-specific standard products for analog, digital, and mixed-signal applications. The company also offers subsystems and modules for the telecommunications, automotive, and industrial markets comprising mobile phone accessories, battery chargers, ISDN power supplies, and in-vehicle equipment for electronic toll payment, as well as provides Smartcard products. Its products are used in various microelectronic applications consisting of automotive products, computer peripherals, telecommunications systems, consumer products, industrial automation, and control systems. The company sells its products through distributors and ret ailers. STMicroelectronics N.V. was founded in 1987 and is headquartered in Geneva, Switzerland.
Advisors' Opinion:- [By Seth Jayson]
STMicroelectronics (NYSE: STM ) reported earnings on July 22. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 29 (Q2), STMicroelectronics met expectations on revenues and missed expectations on earnings per share. - [By ICRAOnline]
Revenue for the last quarter stood at $73.4 million, up 27.9% from the year-ago quarter. This was primarily driven by the growth in memory technology licensing, coupled with impressive performance of its security technology licensing business. During the quarter, Rambus also signed new licensing agreements with tech giant Samsung Electronics, Micron Technology (MU), STMicroelectronics (STM), LSI Semiconductor (LSI) and SK Hynix. However, the company�� LED lighting business failed to make any significant contribution.
- [By Lee Jackson]
STMicroelectronics NV (NYSE: STM) supplies most set-top box chips for Scientific�Atlanta, and also sells chips for disk drives that end up in DVRs; but still has less than a 10% exposure. The consensus target for the stock is $11. Investors do receive an outstanding 4.0% dividend from the company.
- [By Tyler Laundon]
Analog Devices (ADI) is one of the largest semiconductor companies in the motion-sensing space, with a market cap of $15.87 billion. STM Electronics (STM) is a slightly smaller manufacturer; its market cap is $7.6 billion.
No comments:
Post a Comment